Figure 1.

(A) 25-vit-D₃ (major circulating vitamin D metabolite) serum levels during imatinib treatment. Compared to months with higher sunlight exposure measurements were significantly lower in the winter time. The probability to exhibit normal measurements was calculated to be 5.86-fold higher in the summertime than in the wintertime (p=0.016). (B) 1,25-vit-D₃ serum levels during imatinib treatment. No effect of exposure to sunlight could be detected.